ICAM1 and cancer: investigating the preclinical efficacy of intercellular adhesion molecule-1 (ICAM-1)-redirected CAR-Ts for targeting advanced thyroid cancer, it was elucidated that endothelin B receptors are upregulated in cancer tissues which results in the reduced ICAM-1 expression level rendering CAR-Ts incapable of crossing the blood vessels (59).